Explore the Respiratory Hub

Explore the Respiratory Hub

Explore the Respiratory Hub

With almost 100 years of heritage in respiratory disease, Boehringer Ingelheim is dedicated to innovating treatments for and improving the quality of life of patients suffering from chronic respiratory diseases. With you and your patients in mind, we've created the Respiratory Hub – your collection of resources on chronic obstructive pulmonary disease (COPD) and Severe Asthma and our portfolio of respiratory products including: SPIOLTO® Respimat® (tiotropium/olodaterol) and SPIRIVA® Respimat® (tiotropium).

COPD

SPIOLTO® Respimat® is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.

SPIRIVA® Respimat® is indicated as a maintenance bronchodilator treatment to relieve symptoms of patients with COPD.

Severe Asthma

Spiriva® Respimat® is indicated as add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year.

Quick links

Quick links

Resource areas

Some of the content on this website was created before the COVID-19 pandemic. Please refer to national and local guidelines for the latest recommendations on COVID-19 and consider their impact on the materials included on this website.

PC-GB-104688 V2

March 2023

Reporting adverse events

Adverse events should be reported. Reporting form and information can be found atwww.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on0800 328 1627 (freephone).

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.